Get the Stockscreener App
2.05
5.13%
0.10
After Hours:
2.06
0.01
+0.49%
Inovio Pharmaceuticals Inc stock is traded at $2.05, with a volume of 1.49M.
It is up +5.13% in the last 24 hours and down -15.98% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$1.95
Open:
$1.98
24h Volume:
1.49M
Relative Volume:
0.92
Market Cap:
$108.94M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.3366
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
-3.30%
1M Performance:
-15.98%
6M Performance:
+9.04%
1Y Performance:
-57.02%
1-Day Range:
$1.95
$2.10
1-Week Range:
$1.90
$2.23
52-Week Range:
$1.30
$4.97
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
2.05 | 133.97M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
What is the fair value estimate for Inovio Pharmaceuticals Inc. (GBM) stock in 2025Product Launch & Accurate Buy Signal Alerts - newser.com
Inovio (INO) Upgraded to Buy: Here's Why - sharewise.com
Analyzing Inovio Pharmaceuticals Inc. with multi timeframe charts2025 Retail Activity & Precise Swing Trade Entry Alerts - newser.com
INO: Today's Analyst Rating Highlights 20% Target Price Increase - GuruFocus
Individual Investors in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) See 13% Loss in Value of Holdings, Institutional Ownership Remains Low - 富途牛牛
Will Inovio Pharmaceuticals Inc. stock maintain momentum in 20252025 Analyst Calls & Advanced Technical Signal Analysis - Fundação Cultural do Pará
Individual investors invested in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) lost 13% last week, institutions remained on the sidelines - Yahoo Finance
Statistical indicators supporting Inovio Pharmaceuticals Inc.’s strengthTake Profit & Risk Adjusted Swing Trade Ideas - newser.com
Is Inovio Pharmaceuticals Inc. trending in predictive chart modelsQuarterly Market Summary & Risk Managed Investment Strategies - newser.com
Why Inovio Pharmaceuticals Inc. stock is a value investor pickEarnings Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
How to read the order book for Inovio Pharmaceuticals Inc.Weekly Risk Summary & Growth Focused Stock Pick Reports - newser.com
INOVIO Submits FDA Application for First DNA Therapy to Treat Rare HPV Disease - MyChesCo
How reliable is Inovio Pharmaceuticals Inc. (GBM) stock dividend growthWeekly Trend Recap & Low Risk Profit Maximizing Plans - newser.com
Is Inovio Pharmaceuticals Inc. stock attractive after correction2025 Key Lessons & Smart Money Movement Tracker - newser.com
How to use a screener to detect Inovio Pharmaceuticals Inc. breakoutsJuly 2025 Spike Watch & Weekly Chart Analysis and Trade Guides - newser.com
What RSI levels show for Inovio Pharmaceuticals Inc. (GBM) stockMarket Trend Review & Verified Technical Signals - newser.com
Inovio Pharmaceuticals Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Build Wealth Brick by Brick With Us - earlytimes.in
Will Inovio Pharmaceuticals Inc. benefit from macro trends2025 Short Interest & Low Drawdown Investment Strategies - newser.com
Why Inovio Pharmaceuticals Inc. stock is rated strong buyJobs Report & Daily Entry Point Alerts - newser.com
Inovio Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Can Inovio Pharmaceuticals Inc. (GBM) stock surprise markets with earnings2025 Top Decliners & Expert Approved Trade Ideas - newser.com
Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress (NASDAQ:INO) - Seeking Alpha
Inovio Pharmaceuticals (INO) Receives a Buy from Oppenheimer - The Globe and Mail
Inovio prices $25 million public offering of common stock By Investing.com - Investing.com Philippines
Inovio Pharmaceuticals drops 6%, proposes equity offering - MSN
Inovio outlines mid-2026 launch for INO-3107 as BLA submission progresses - MSN
Inovio Pharmaceuticals Q3 2025 Earnings Preview - MSN
Inovio plans public offering to fund DNA medicine development - The Pharma Letter
Inovio announces pricing of $25 million public offering - MarketScreener
INOVIO Shares Drop 10% After Discounted $25 Million Public Offering - MSN
Inovio (INO) Prices Public Offering at $1.90 Per Share - GuruFocus
INOVIO stock falls after pricing $25 million public offering at discount - Investing.com Nigeria
Inovio Pharma falls on $25 mln stock sale - TradingView
INOVIO Announces Pricing of $25 Million Public Offering - GuruFocus
INOVIO Pharmaceuticals (INO) Prices Public Offering at $1.90 Per Share - GuruFocus
Inovio prices $25 million public offering of common stock - Investing.com India
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):